Fiztasovimab  (Synonyms: NPC-21; EV2038)

Fiztasovimab (NPC-21; EV2038) is a fully human IgG1λ mAb against human cytomegalovirus (hCMV). Fiztasovimab acts neutralizing activity by binding to the antigenic domain 1 of glycoprotein B on hCMV envelope. Fiztasovimab inhibits cell-to-cell transmission of hCMV^[1].

Human IgG1 lambda1

Human IgG1 lambda1, Isotype Control

Human

Fiztasovimab 是从健康供体 EB 病毒转化的外周 B 细胞中分离出来的^[1]。
Fiztasovimab 具有广泛的中和活性，对 4 种实验室菌株 (AD169, Towne, Davis, Merlin) 和 42 种日本临床分离株 (包括 gcv 耐药菌株) 均有作用^[1]。
Fiztasovimab 对 MRC-5 人胚胎成纤维细胞和成人视网膜色素上皮细胞具有抗 hMCV 活性，IC₅₀ 为 13-105 ng/mL, IC₉₀ 为 0.208-1.026 μg/mL^[1]。
Fiztasovimab 还能抑制成人视网膜色素上皮细胞 hCMV 分离株的细胞间感染，IC₉₀ 为 13-19 μg/mL^[1]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

2467411-25-0

液体

Colorless to light yellow

Shipping with dry ice.

Please store the product under the recommended conditions in the Certificate of Analysis.

• 
  Human IgG1 lambda

• 
  Immobilized Human cytomegalovirus (HCMV) Glycoprotein B/gB Protein can bind Fiztasovimab. The EC₅₀ for this effect is 20.15 ng/mL.

• [1]. Furihata K, et al. Pharmacokinetics, Safety, and Tolerability of NPC-21, an Anti-Cytomegalovirus Monoclonal Antibody, in Healthy Japanese and White Adult Men: A Randomized, Placebo-Controlled, First-in-Human Phase 1 Study. Clin Pharmacol Drug Dev. 2022 Jun;11(6):707-716.  [Content Brief]